Stem Cell Innovations and ALS Association announce collaboration

14-Dec-2006

Stem Cell Innovations, Inc. and The ALS Association announced a two-year discovery alliance. Stem Cell Innovations (SCI) will develop human motor neuron models based on its proprietary PluriCell(TM) technology that can be used for high-throughput screening. Subsequently, the cell models will be used by alliance partner Galapagos to discover novel drug targets for ALS. Under the terms of the agreement, SCI will receive 400,000 Euros ($512,000) from The ALS Association, upon completion of certain milestones. In addition, SCI has the option to further develop certain cell-therapy applications based on results identified in the program.

According to the company, funding from The ALS AssociationZs translational program, Translational Research Advancing Therapy for ALS (TREAT ALS), is the largest to date focused on drug development. TREAT ALS seeks new avenues to therapeutics and puts into place a clinical trials process that will be ready when any new candidates are identified. Several pilot clinical trials of existing candidates are already underway with TREAT ALS funding.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances